Regenerative medicine, particularly stem cell-based therapies, may offer new hope and the potential to revisit the approach to treating cutaneous radiation syndrome (CRS) — a condition caused by high doses of radiation that can damage the skin. ?

One promising approach is adult mesenchymal stem/stromal cell therapy (MSCT), a technique which uses stem cells to promote healing and tissue regeneration, offering potential for those dealing with the consequences of radiation exposure. By repairing damaged skin and rejuvenating affected areas, adult MSCT helps alleviate physical symptoms and enhances patients’ emotional well-being— helping patients regain confidence and reclaim their daily lives. As research advances, therapies like MSCT could reshape how CRS treatment is approached, while ensuring that no patient has to endure the lingering effects of radiation exposure without the support they need.

The new CRP titled ‘Mesenchymal stem cell based regenerative medicine technologies for treatment of radiation induced lesions,’ will explore the potential of adult MSCT to address the complex challenge of radiation-induced lesions.

“Regenerative medicine — particularly adult MSCT — has the potential to improve healing and restore quality of life for those affected,” said May Abdel-Wahab, Director of the IAEA Division of Human Health. “This project represents a major step forward in the effort to alleviate suffering and deliver transformative care for individuals living with untoward consequences of radiation exposure.”

Jean-Jacques Lataillade, Director of the Armed Forces Blood Transfusion Centre at the French Defence Health Service, who contributed to the development of the project, said: “Mesenchymal stem cells represent a promising modality in regenerative medicine, attributed to their inherent ability to migrate to damaged tissues, modulate immune and inflammatory responses, promote cell survival and tissue repair, as well as stimulate angiogenesis.”

This CRP aims to raise awareness and refine the techniques of adult MSCT, tissue engineering and biobanking technology, specifically for CRS treatment. By focusing on cutting-edge research along with pre-clinical and clinical studies that adhere to regulatory guidelines, this initiative is set to pave the way for advancements in patient care.

Research organizations interested in joining the CRP must submit their Proposals for Research Contract or Agreement by email, no later than 30 November 2025, to the IAEA’s?Research Contracts Administration Section using the appropriate template on the?Coordinated Research Activities web site. The same template can be used for both research contract and technical contract.

The IAEA encourages research organizations to involve, to the extent possible, women and young researchers in their proposals. Collaborations between research organizations and local mining companies will be an advantage.

Further information related to this CRP can be found?here